BVS (Bioventus) Moat Score: 4/10 (As of Jun. 30, 2026)


BVS Bioventus Inc BVS
66 GF Score
Price $9.78
GF Value $6.79
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bioventus Moat Score?

Bioventus BVS 66 Moat Score is 4 as of Jun. 30, 2026. GuruFocus rates BVS with a GF Score™ of 66/100 and a GF Value™ of $6.79 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Bioventus ranks better than 83.33% on this metric.

Bioventus has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Bioventus has Narrow Moat: Bioventus Inc has a discernible but modest moat due to its niche market presence and some proprietary technology. However, it lacks significant market leadership, customer loyalty, and regulatory barriers, limiting its competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bioventus might have Narrow Moat - Discernible but modest moat.

Bioventus  (NAS:BVS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bioventus Moat Score Related Terms

BVS vs SSII, TCMD, CERS: Moat Score Comparison

For the Medical Devices subindustry, Bioventus's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioventus Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioventus's Moat Score distribution charts can be found below:

* The bar in red indicates where Bioventus's Moat Score falls into.


BVS
66GF Score
Bioventus Inc BVS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Bioventus (BVS) has a Moat Score of 4 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Bioventus ranks #141 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 16.7%.
Is Bioventus' Moat Score too high?
Bioventus' current Moat Score is 4. Based on the distribution chart, Bioventus ranks #141 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bioventus has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bioventus' Moat Score compare to SSII and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Bioventus ranks #141 out of 846 companies for Moat Score. This places Bioventus in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Bioventus's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventus stock overvalued right now?
Based on GuruFocus' analysis, Bioventus (BVS) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.79, compared to a current price of $9.78 — trading 44% above its estimated fair value. The current Moat Score is 4. Bioventus' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Bioventus (BVS), the current Moat Score is 4 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioventus (BVS) Overvalued in 2026?

Based on GuruFocus' analysis, Bioventus stock appears to be overvalued. The current stock price of $9.78 is trading 44% above its estimated GF Value™ of $6.79. GuruFocus considers Bioventus to be Significantly Overvalued.

Key valuation signals for BVS:

  • Moat Score: 4
  • GF Value™: $6.79 vs. price of $9.78 (44% above fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the BVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioventus Business Description

Other Exchanges 4B8:Germany
Address 4721 Emperor Boulevard, Suite 100, Durham, NC, USA, 27703
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
66GF Score

Get the complete analysis for BVS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.78
Price
$6.79
GF Value